Impact of Patient and Model of Care Factors on Titration and Tolerability of Sacubitril/Valsartan: An Early Australian Real-World Experience

Sacubitril/valsartan was shown to be superior to enalapril in the Prospective Comparison of angiotensin receptor neprilysin inhibitor with an angiotensin converting enzyme inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) study. However, the study design raised uncertainty about the potential real-world tolerability amongst less well selected cohorts. We aimed to examine the real-world tolerability and factors associated with successful titration of sacubitril/valsartan.

Source: Heart, Lung and Circulation - April 8, 2020 Category: Cardiology Authors: Alexander Dashwood, Cassandra Vale, Shaaheen Laher, Fiona Chui, Haunnah Rheault, Jaclyn Gan, Yee Weng Wong Tags: Original Article Source Type: research